Janssen Inc. v. Apotex Inc.
Source text
Janssen Inc. v. Apotex Inc. Court (s) Database Federal Court Decisions Date 2021-01-06 Neutral citation 2021 FC 3 File numbers T-84-19 Decision Content Date: 20210106 Docket: T-84-19 Citation: 2021 FC 3 Ottawa, Ontario, January 6, 2021 PRESENT: The Honourable Mr. Justice Phelan BETWEEN: JANSSEN INC, JANSSEN ONCOLOGY, INC AND BTG INTERNATIONAL LTD Plaintiffs and APOTEX INC Defendant JUDGMENT THIS COURT ADJUDGES, ORDERS AND DECLARES that: Canadian Patent No. 2,661,422 is, and has always been, invalid, void and of no effect by reasons of obviousness/obvious to try as asserted by the Defendant and is to be removed from the Patent Register. Except for this declaration of invalidity, the making, constructing, using or selling of APO-ABIRATERONE, orally administered tablets containing abiraterone acetate in dosage strengths of 250 mg and 500 mg film-coated tablets by Apotex Inc in accordance with its Supplemental Abbreviated New Drug Submission No. 222284 would infringe the Asserted Claims. This action and counterclaim are dismissed with costs to the Defendant, the whole of which is to be the subject of a further determination by the Court. blank “Michael L. Phelan” blank Judge …
Full judgment (source text)
Mirrored from decisions.fct-cf.gc.ca — the linked original is authoritative.
Janssen Inc. v. Apotex Inc. Court (s) Database Federal Court Decisions Date 2021-01-06 Neutral citation 2021 FC 3 File numbers T-84-19 Decision Content Date: 20210106 Docket: T-84-19 Citation: 2021 FC 3 Ottawa, Ontario, January 6, 2021 PRESENT: The Honourable Mr. Justice Phelan BETWEEN: JANSSEN INC, JANSSEN ONCOLOGY, INC AND BTG INTERNATIONAL LTD Plaintiffs and APOTEX INC Defendant JUDGMENT THIS COURT ADJUDGES, ORDERS AND DECLARES that: Canadian Patent No. 2,661,422 is, and has always been, invalid, void and of no effect by reasons of obviousness/obvious to try as asserted by the Defendant and is to be removed from the Patent Register. Except for this declaration of invalidity, the making, constructing, using or selling of APO-ABIRATERONE, orally administered tablets containing abiraterone acetate in dosage strengths of 250 mg and 500 mg film-coated tablets by Apotex Inc in accordance with its Supplemental Abbreviated New Drug Submission No. 222284 would infringe the Asserted Claims. This action and counterclaim are dismissed with costs to the Defendant, the whole of which is to be the subject of a further determination by the Court. blank “Michael L. Phelan” blank Judge
Source: decisions.fct-cf.gc.ca